Sylvia ODT 75mg Tablet

✔️ Dosage & Administration | Sylvia ODT Tablet

Acute Treatment of Migraine: The recommended dose is 75 mg orally as needed. Do not take more than 75 mg within 24 hours. The safety of using more than 18 doses in 30 days has not been established.

Preventive Treatment of Episodic Migraine: The recommended dose is 75 mg orally every other day.

Take Sylvia ODT exactly as prescribed by your doctor. Do not exceed the recommended dose. Follow the product-specific instructions for taking the orally disintegrating tablet.

Children: The safety and effectiveness of Sylvia ODT have not been established in pediatric patients.

Older adults: Available studies have not shown clinically significant differences in drug exposure between older and younger adults. However, clinical studies included limited numbers of patients aged 65 years and older.

Hepatic impairment: No dosage adjustment is generally required in mild or moderate hepatic impairment. Avoid use in patients with severe hepatic impairment (Child-Pugh Class C).

Renal impairment: No dosage adjustment is generally required in mild, moderate, or severe renal impairment. Avoid use in patients with end-stage renal disease with creatinine clearance below 15 mL/min or those requiring dialysis, as use has not been adequately studied in these populations.

✔️ Side Effects | Sylvia ODT Tablet

Common side effects may include:

• Nausea
• Stomach pain
• Indigestion

Serious allergic reactions may also occur, including rash and difficulty breathing. Seek immediate medical attention if breathing difficulties, facial or throat swelling, or other signs of a severe allergic reaction develop.

✔️ Interaction

• Strong CYP3A4 inhibitors: Avoid using Sylvia ODT with strong CYP3A4 inhibitors because they may substantially increase rimegepant exposure.
• Moderate CYP3A4 inhibitors: These may increase rimegepant levels. Avoid taking another dose within 48 hours when used together.
• Moderate or strong CYP3A inducers: Avoid concomitant use because these medicines may reduce rimegepant exposure and decrease its effectiveness.
• Potent P-glycoprotein (P-gp) inhibitors: Medicines such as amiodarone, cyclosporine, lapatinib, quinidine and ranolazine may increase rimegepant exposure. Avoid taking another dose within 48 hours when used together.

✔️ Contraindications:

Sylvia ODT should not be used by patients with a history of hypersensitivity to rimegepant or any of the tablet's ingredients.

✔️ Pregnancy and Breastfeeding

There is insufficient information to determine the risk of rimegepant during pregnancy. Data are also limited regarding its presence in human breast milk, its effects on breastfed infants, and its impact on milk production.

Consult a healthcare professional before using Sylvia ODT during pregnancy or breastfeeding.

✔️ Precautions and Warnings

Hypersensitivity reactions may occur shortly after taking Sylvia ODT or several days later. If an allergic reaction develops, discontinue the medicine and seek appropriate medical care. Serious or delayed reactions require prompt assessment.

Use this medicine only under medical supervision, particularly if you have liver or kidney disease or take medicines that may interact with rimegepant.

✔️ Storage:

Store below 25°C, protected from light and moisture. Keep out of the reach of children.